Fulvestrant, formerly ICI 182,780, is as effective as anastrozole in postmenopausal women with advanced breast cancer progressing after prior endocrine treatment.
By A. Howell, J. Robertson, J. Albano, A. Aschermannová, L. Mauriac, U. R. Kleeberg, I. Vergote, B. Erikstein, A. Webster, C. Morris. Journal of Clinical Oncology, 2002
680 citations recorded by the source corpus.
Subfields: Cancer Research, Genetics, Pulmonary and Respiratory Medicine
View Paper: https://www.semanticscholar.org/paper/1633f633dc4fdc27563daa3b11717d16e51179c4
How researchers see this paper
The researchers whose trusted networks rank it highest, strongest advocate first. Every researcher gets a different order.
In Cancer Research
In Genetics
Citations in the corpus
- Tamoxifen: a most unlikely pioneering medicine (2003, background): “These new targeted agents are proving to be effective anticancer agents and seem to be superior to tamoxife”
- Mechanisms of tamoxifen resistance. (2004, background): “In fact up to 20% of patients who have relapsed on tamoxifen respond to aromatase inhibitors or to the ER-down-regulator fulves-trant suggesting that the ER continues to regulate growth even in many tamoxifen-resistant patients (Howell et al. 2002, Osborne et al. 2002).”
- Results of the CONFIRM phase III trial comparing fulvestrant 250 mg with fulvestrant 500 mg in postmenopausal women with estrogen receptor-positive advanced breast cancer. (2010, background): “treatments have similar efficacy and an acceptable safety profile with a low incidence of withdrawals.(4,5) These results led to the registration of fulvestrant 250”